Drugs / Dipyridamole
Dipyridamole
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | PERSANTINE | — | 1986-12-22 | fda.gov ↗ |
| Approved | US (FDA) | PERSANTINE | — | 1961-12-06 | fda.gov ↗ |
Trials 41
1960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00960817 | — | coronary artery disorder | Hillel Yaffe Medical Center | Unknown | No outcome recorded |
| Phase 19 trials | ||||||
| Phase 1 | NCT02262793 | May → Jul 2004 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02273557 | Jan → Feb 2003 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02273544 | Sep → Oct 2002 | — | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT02273518 | Apr → May 2001 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00223717 | Jan 2001 → Jan 2017 | hypertensive disorder | Vanderbilt University | Completed | No outcome recorded |
| Phase 1 | NCT02226926 | Jul → Sep 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02273505 | Apr → May 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02268773 | Jan → May 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02278302 | Aug 1999 → Mar 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1/21 trial · 1 missed | ||||||
| Phase 1/2 | NCT02121756 | Jul 2014 → Oct 2017 | HIV infectious disease | Sharon Riddler | Completed | Missed primary |
| Phase 215 trials · 2 missed | ||||||
| Phase 2 | NCT06824454 | May 2025 → May 2027 expected | hypophosphatemia | Stanford University | Recruiting | No outcome recorded |
| Phase 2 | NCT05166876 | Feb → Jun 2022 | COVID-19 | Clear Creek Bio, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04391179 | May 2020 → Feb 2021 | COVID-19 | University of Michigan | Completed | Missed primary |
| Phase 2 | NCT04424901 | May 2020 → Mar 2022 | pneumonia, vascular insufficiency disorder | UConn Health | Terminated | No outcome recorded |
| Phase 2 | NCT06268470 | Jun 2018 → Mar 2024 | chronic urticaria | Chulalongkorn University | Unknown | No outcome recorded |
| Phase 2 | NCT02782260 | Jul 2016 → Oct 2017 | dry eye syndrome, pterygium | Ariel University | Unknown | No outcome recorded |
| Phase 2 | NCT02565693 | Sep 2014 → Jan 2021 | atrial fibrillation, intracerebral hemorrhage | UMC Utrecht | Completed | Missed primary |
| Phase 2 | NCT01612377 | Mar 2012 → Jul 2013 | rheumatoid arthritis | Zalicus | Terminated | No outcome recorded |
| Phase 2 | NCT01593644 | Jun 2011 → Mar 2013 | ischemic disease | Adenobio N.V | Unknown | No outcome recorded |
| Phase 2 | NCT00521989 | Aug 2007 → Jul 2009 | osteoarthritis, knee | Zalicus | Terminated | No outcome recorded |
| Phase 2 | NCT00276146 | May 2005 → ? | sickle cell disease | Children's Hospital Medical Center, Cincinnati | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00747214 | Nov 2004 → Sep 2006 | rheumatoid arthritis | Zalicus | Completed | No outcome recorded |
| Phase 2 | NCT00003018 | Sep 1997 → Jan 2002 | pancreatic adenocarcinoma | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 2 | NCT00002487 | Jul 1991 → ? | ovarian cancer | Ottawa Regional Cancer Centre | Unknown | No outcome recorded |
| Phase 2 | NCT00000527 | Aug 1986 → Nov 1998 | carotid stenosis, heart disorder | Emory University | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07199504 | Sep 2025 → Dec 2026 expected | restless legs syndrome | Yunfeng Xia | Recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT04410328 | Oct 2020 → Oct 2021 | COVID-19 | Rutgers, The State University of New Jersey | Completed | No outcome recorded |
| Phase 3 | NCT00000510 | Sep 1983 → Sep 1988 | intermediate coronary syndrome, myocardial ischemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 3 | NCT00000496 | Dec 1979 → Dec 1982 | coronary artery disorder, myocardial ischemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 47 trials · 2 missed | ||||||
| Phase 4 | NCT01091571 | Mar → Oct 2010 | — | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01295567 | Dec 2009 → Feb 2012 | ischemic disease | Radboud University Medical Center | Completed | Missed primary |
| Phase 4 | NCT00767663 | Oct 2008 → Jan 2010 | atherosclerosis, coronary artery disorder | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00562588 | Jul 2007 → Feb 2009 | cerebral infarction | Boehringer Ingelheim | Completed | Missed primary |
| Phase 4 | NCT00129038 | Apr 2004 → Jan 2007 | coronary atherosclerosis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT00763009 | Sep 2002 → Jul 2009 | coronary artery disorder | UConn Health | Terminated | No outcome recorded |
| Phase 4 | NCT00161070 | Jul 1997 → Dec 2006 | arteriosclerosis disorder, transient ischemic attack | UMC Utrecht | Completed | Mixed |
| Phase not applicable4 trials | ||||||
| — | NCT06053021 | Sep 2023 → Oct 2025 | ischemic stroke, thrombocytopenia | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT01781611 | Feb 2013 → May 2017 | systemic lupus erythematosus | Oklahoma Medical Research Foundation | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00268554 | Dec 2005 → Jul 2006 | — | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT00349973 | May 2001 → Sep 2008 | schizoaffective disorder, schizophrenia, schizophreniform disorder | University of Maryland, Baltimore | Completed | No outcome recorded |
| Comparator or background therapy23 trials | ||||||
| Phase 1 | NCT01303445 Comparator | Mar → Apr 2011 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1/2 | NCT03591471 Comparator | Sep 2014 → Dec 2018 | immunoglobulin A vasculitis | Henan University of Traditional Chinese Medicine | Unknown | No outcome recorded |
| Phase 2 | NCT01369745 Comparator | Jun 2011 → Aug 2012 | rheumatoid arthritis | Zalicus | Completed | No outcome recorded |
| Phase 2 | NCT00551707 Comparator | Oct 2007 → Nov 2008 | rheumatoid arthritis | Zalicus | Completed | No outcome recorded |
| Phase 3 | NCT03354273 Background | Jun 2018 → May 2022 | coronary artery disorder | GE Healthcare | Completed | Met primary |
| Phase 3 | NCT01661322 Comparator | Apr 2009 → Sep 2017 | ischemic stroke | University of Nottingham | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00238667 Comparator | Nov 2005 → May 2014 | carotid artery dissection, stroke disorder, vertebral artery dissection | St George's, University of London | Completed | No outcome recorded |
| Phase 4 | NCT04666454 Comparator | Dec 2020 → Dec 2028 expected | Tako-tsubo cardiomyopathy | Vastra Gotaland Region | Recruiting | No outcome recorded |
| Phase 4 | NCT04645550 Background | Nov 2020 → Dec 2023 | cirrhosis of liver, portal hypertension, splenic disorder, venous thromboembolism | Northern Jiangsu People's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02238444 Background | Sep 2014 → Sep 2019 | cirrhosis of liver, hypertensive disorder, venous thromboembolism | Yangzhou University | Unknown | No outcome recorded |
| Phase 4 | NCT02247414 Background | Sep 2014 → Sep 2017 | cirrhosis of liver, hypertensive disorder, portal vein thrombosis | Yangzhou University | Completed | No outcome recorded |
| Phase 4 | NCT01613755 Comparator | Apr → Jul 2012 | diabetes mellitus | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00808314 Comparator | Dec 2008 → Dec 2010 | coronary artery disorder | Cardiovascular Imaging Technologies | Unknown | No outcome recorded |
| Phase 4 | NCT00457405 Comparator | Jun → Oct 2007 | atherosclerosis, ischemic disease | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00430170 Comparator | Jan → Mar 2007 | ischemic disease | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00560079 Comparator | Nov 2003 → Apr 2005 | manic bipolar affective disorder | Hospital Espirita de Porto Alegre | Completed | Met primary |
| Phase 4 | NCT00153062 Comparator | Aug 2003 → Apr 2008 | stroke disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT02251184 Comparator | Oct → Nov 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| — | NCT06899399 Comparator | Oct 2024 → Jul 2028 expected | internal carotid artery stenosis | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| — | NCT05304455 Background | Apr 2022 → May 2023 | cirrhosis of liver, portal hypertension, portal vein thrombosis | Northern Jiangsu People's Hospital | Completed | No outcome recorded |
| — | NCT02630862 Comparator | Sep 2010 → Jun 2014 | atherosclerosis, carotid stenosis, stroke disorder | University of Roma La Sapienza | Completed | No outcome recorded |
| — | NCT00738894 Background | Dec 2008 → Apr 2017 | transient ischemic attack | W.L.Gore & Associates | Completed | No outcome recorded |
| — | NCT00906035 Comparator | Sep 2002 → Mar 2010 | peripheral arterial disease | University of Pennsylvania | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2012-02-03 | Boehringer Ingelheim | Results Study Finds No Drug-Drug Interaction Between Aggrenox® (aspirin/extended-release dipyridamole) 25mg/200mg Capsules and Omeprazole, a Widely Used PPI prnewswire.com ↗
The 90 percent confidence intervals of the Cmax and AUC of the dipyridamole component fell within the accepted window of 80 – 125 percent in both dosing sequences indicating no significant interaction. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2012-02-03 | Boehringer Ingelheim | Study Finds No Drug-Drug Interaction Between Aggrenox® (aspirin/extended-release dipyridamole) 25mg/200mg Capsules and Omeprazole, a Widely Used PPI prnewswire.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 65 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dipyridamole | “To investigate the relative bioavailability of telmisartan respectively of dipyridamole after concomitant administration of 80 mg telmisartan in Micardis® and 25 mg...” NCT02262793 ↗62“The objective of the current study is to investigate if a drug-drug interaction occurs with the administration of omeprazole 80 mg q.d. at steady state on the pharmacokinetics...” NCT01303445 ↗ “Comparison of Pharmacokinetics of Dipyridamole in Asasantin Extended Release (ER) 200/25 mg Capsules Bid and in a Combination of Persantin Immediate Release Tablets (100 mg...” NCT02273505 ↗ “Pharmacologic stress agents were restricted to the following 3 agents, as permitted by local marketing authorisations and availability: adenosine, dipyridamole, and regadenoson.” NCT03354273 ↗ “Participants will receive intensive medical management, including aspirin (75-325 mg/day) or alternative antiplatelet agents (clopidogrel/dipyridamole) for intolerance.” NCT06899399 ↗ “modified-release dipyridamole (200 mg) bd versus acetylsalicylic acid (75 mg dispersible tablet once daily) in its effect on inhibition of thromboxane B2 formation” NCT02268773 ↗ “we randomly assigned patients to receive 25 mg of aspirin plus 200 mg of extended-release dipyridamole twice daily or to receive 75 mg of clopidogrel daily.” PMID 18753638 ↗ Aug 2008 “CRx-102 is a synergistic combination drug candidate containing the cardiovascular drug dipyridamole and a very low dose of the glucocorticoid prednisolone.” NCT00521989 ↗ “Bioavailability of Dipyridamole After Asasantin (Extended Release 200mg Dipyridamole/25mg ASA) in 3 Experimental Formulations” NCT02273544 ↗ “Bioavailability of Dipyridamole of Asasantin p.o. (Extended Release 200 mg Dipyridamole/25 mg ASA)” NCT02273557 ↗ “measurements of dipyridamole plasma levels” NCT02226926 ↗ |
| Known as | Dipyradimole | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01661322 ↗ |
| Known as | ER-DP | “To investigate the relative bioavailability of telmisartan respectively of dipyridamole after concomitant administration of 80 mg telmisartan in Micardis® and 25 mg...” NCT02262793 ↗1“receive either 25 mg aspirin (ASA) and 200 mg extended-release dipyridamole (ER-DP) twice a day or 75 mg clopidogrel once a day” PMID 18757238 ↗ Aug 2008 |
| Known as | NSC-515776 | “Methotrexate, MTX, NSC-740; with Dipyridamole, DP, NSC-515776.” NCT00002487 ↗ |
| Known as | Persantin retard | “dipyridamole (Persantin retard; 200 mg twice daily)” NCT00457405 ↗ |
| Action | Inhibit | “platelet inhibitor drugs dipyridamole and aspirin” NCT00000496 ↗ |
| Modality | Other / unclassified | “the cardiovascular drug dipyridamole” NCT00551707 ↗ |
| Route | Oral | “pre- and post-operative oral administration of platelet-inhibiting drugs” NCT00000527 ↗ |